Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TIL, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Autologous Tumor Infiltrating Lymphocyte | Advanced Cutaneous Melanoma | Phase 2 · NCT05050006 | Terminated |
| AXN-2510 | Solid Tumor, Adult | Phase 1 · NCT07159828 | Terminated |
| Anti-FOLR1 CoStAR-expressing Autologous | Epithelial Ovarian Cancer | Phase 1 · NCT05397093 | Terminated |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TIL holds $69.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $3M/quarter from operations, an estimated runway of 69.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TIL files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TIL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →